Perella Weinberg Partners Capital Management LP Bristol Myers Squibb CO Transaction History

Perella Weinberg Partners Capital Management LP

$935 Million
Q1 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 08, 2019	SELL	$42.77 - $50.71 $485,396 - $575,507	-11,349 Closed	0 $0
Q2 2019 Jul 22, 2019	SELL	$44.62 - $49.34 $360,618 - $398,765	-8,082 Reduced 41.59%	11,349 $515,000
Q1 2019 May 06, 2019	BUY	$45.12 - $53.8 $85,953 - $102,489	1,905 Added 10.87%	19,431 $99,000
Q4 2018 Jan 29, 2019	BUY	$48.76 - $63.23 $854,567 - $1.11 Million	17,526 New	17,526 $911,000
Q2 2018 Jul 24, 2018	SELL	$50.53 - $62.98 $6.82 Million - $8.5 Million	-134,927 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$59.92 - $68.98 $4.34 Million - $5 Million	72,499 Added 116.13%	134,927 $8.53 Million
Q4 2017 Feb 14, 2018	SELL	$59.94 - $65.35 $2.34 Million - $2.56 Million	-39,118 Reduced 38.52%	62,428 $3.83 Million
Q3 2017 Nov 14, 2017	SELL	$55.23 - $63.74 $1.53 Million - $1.77 Million	-27,752 Reduced 21.46%	101,546 $6.47 Million
Q2 2017 Aug 14, 2017	BUY	N/A	129,298	129,298 $7.2 Million

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

Vanguard Group Inc Valley Forge, PA

187M
Shares

$9.92 Billion
0.15% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$8.44 Billion
0.15% of portfolio
State Street Corp Boston, MA

91.4M
Shares

$4.86 Billion
0.17% of portfolio
Jpmorgan Chase & CO New York, NY

74.6M
Shares

$3.97 Billion
0.27% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

59.1M
Shares

$3.14 Billion
0.47% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Perella Weinberg Partners Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Perella Weinberg Partners Capital Management LP with notifications on news.

Account